WEBVTT

00:00:00.110 --> 00:00:02.939
A pregnancy plan changes the visit.

00:00:03.097 --> 00:00:07.095
A fictional patient uses injectable
Wegovy only for weight management.

00:00:07.269 --> 00:00:10.809
She hopes to start trying to conceive
next month and asks whether she can

00:00:10.810 --> 00:00:13.277
continue until a positive pregnancy test.

00:00:13.541 --> 00:00:18.011
What needs to change? For this
weight-management use, the current Wegovy

00:00:18.012 --> 00:00:21.979
prescribing information calls for
discontinuation at least two months before a

00:00:21.980 --> 00:00:26.186
planned pregnancy. Her proposed timeline
therefore needs discussion now with

00:00:26.187 --> 00:00:28.320
the prescribing clinician and obstetric team.

00:00:28.661 --> 00:00:33.060
Do not apply one medicine's stopping
interval to every GLP-1 treatment.

00:00:33.252 --> 00:00:37.894
Confirm the product, formulation,
indication, dose and last dose.

00:00:38.030 --> 00:00:41.443
Ask about reproductive plans without
making assumptions about age or

00:00:41.444 --> 00:00:46.156
contraception. If a patient also has
diabetes, stopping a medicine is only

00:00:46.164 --> 00:00:47.756
one part of the transition.

00:00:47.998 --> 00:00:51.394
Arrange active glucose management
and an agreed treatment plan.

00:00:51.563 --> 00:00:55.829
Rising glucose or concerning symptoms
need timely assessment, not simply a

00:00:55.830 --> 00:00:57.130
referral placed in the chart.

00:00:57.652 --> 00:01:01.832
Explain who will make the medication
decision, who is responsible while

00:01:01.833 --> 00:01:05.288
appointments are pending, and how the
patient should contact the team if her

00:01:05.289 --> 00:01:09.216
plans or health change. Ask her to
explain the next step in her own words.

00:01:09.710 --> 00:01:14.054
The takeaway is simple: verify the product,
apply the appropriate instruction,

00:01:14.190 --> 00:01:18.483
and preserve ongoing care. The full
activity includes the references and the

00:01:18.484 --> 00:01:21.722
separate contraception and
unexpected-exposure cases.